Amoxapine
| Amoxapine | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 313.80 g/mol [1] |
| Melting point | 175-176 [1] |
| Solubility | 1.71e-01 g/L [1] |
| Predicted LogP | 2.6 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C17H16ClN3O |
| IUPAC name | 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine |
| SMILES | C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl |
| InChI | InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2 |
| InChIKey | QWGDMFLQWFTERH-UHFFFAOYSA-N |
| CAS number | 14028-44-5 |
| UNII | R63VQ857OT |
| PubChem CID | 2170 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 8–10 hours (30 hours for chief active metabolite) |
| Metabolism | Hepatic (cytochrome P450 system) |
| Excretion | Renal (60%), feces (18%)[3] |
| Routes of administration | Oral |
Amoxapine (also known as Asendin, Demolox, Amoxan, Desmethylloxapin, Amoxapina, Asendis, Amoxapinum, Cl 67772, Defanyl or Cl-67772) is a substance of the 1-benzylpiperazine class.
Chemistry
Stereochemistry []
Amoxapine is achiral.
Druglikeness
Lipinski's rule of five
Amoxapine matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- antidepressants (N06A)
- non-selective monoamine reuptake inhibitors (N06AA)
- amoxapine (N06AA17)
MeSH Classification
- antidepressive agents, tricyclic (M0001387)
- neurotransmitter uptake inhibitors (M0021830)
- dopamine antagonists (M0027734)
- adrenergic uptake inhibitors (M0028095)
- selective serotonin reuptake inhibitors (M0556972)
Mechanism of action []
Amoxapine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT). [1]
Interactions []
Medical side effects []
97 side effects listed on drug labels in SIDER 4.1 (amoxapine).
- Somnolence
- Dry mouth
- Constipation
- Vision blurred
- Lymphadenitis
- Alopecia
- Decreased appetite
- Atrial fibrillation
- Delusion
- Eosinophilia
- Gynaecomastia
- Hallucination
- Atrioventricular block
- Hepatitis
- Jaundice
- Myocardial infarction
- Acute coronary syndrome
- Pancreatitis
- Ileus paralytic
- Petechiae
- Purpura
- Vascular purpura
- Stomatitis
- Cerebrovascular accident
- Thrombocytopenia
- Pollakiuria
- Arrhythmia supraventricular
- Tongue discolouration
- Parotid gland enlargement
- Testicular swelling
- Abdominal pain
- Gastrointestinal pain
- Agranulocytosis
- Asthenia
- Fatigue
- Ataxia
- Confusional state
- Feeling abnormal
- Libido decreased
- Disturbance in sexual arousal
- Diarrhoea
- Dizziness
- Syncope
- Oedema
- Dermatitis
- Rash
- Body temperature increased
- Drug fever
- Flatulence
- Headache
- Hypertension
- Hypotension
- Inappropriate antidiuretic hormone secretion
- Leukopenia
- Mydriasis
- Nasal congestion
- Nausea
- Nervousness
- Tension
- Neuroleptic malignant syndrome
- Nightmare
- Hypoaesthesia
- Sensory loss
- Palpitations
- Pruritus
- Convulsion
- Shock
- Loss of consciousness
- Tachycardia
- Tinnitus
- Tremor
- Urticaria
- Vasculitis
- Vomiting
- Weight increased
- Urinary retention
- Accommodation disorder
- Menstruation irregular
- Dyspepsia
- Disorientation
- Agitation
- Extrapyramidal disorder
- Disturbance in attention
- Mental disability
- Dysgeusia
- Galactorrhoea
- Paraesthesia
- Tingling sensation
- Hypomania
- Erectile dysfunction
- Painful ejaculation
- Lacrimation increased
- Increased appetite
- Coordination abnormal
- Tardive dyskinesia
- Insomnia
- Breast enlargement
Indications
- Agitation
- Anxiety
- Depression
- Depressive disorder
- Depressive symptom
- Psychotic disorder
Legal status []
- Australia: Amoxapine is a Schedule 4.
- Brazil: Amoxapine is a C1.[4]
- United States: Amoxapine is Prescription only.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 2170, Amoxapine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/2170
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Amoxapine. UNII: R63VQ857OT. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/R63VQ857OT
Asendin, (amoxapine) dosing, indications, interactions, adverse effects, and more. Medscape Reference. http://reference.medscape.com/drug/amoxapine-342937#showall
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 10:56:09 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 10:56:05 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 10:56:05 |
| gsrs | ok | 2026-11-20 10:56:06 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014683) | 2026-11-20 10:56:05 |
| kegg | ok | 2026-11-20 10:56:07 |
| pubchem | ok | 2026-11-20 10:56:05 |
| missing (no r/tripreports posts mention it) | 2026-11-20 10:56:05 | |
| sider | ok | 2026-11-20 10:56:05 |
| structure | ok | 2026-11-20 10:56:05 |
| wikipedia | ok | 2026-11-20 10:56:05 |